Romiplostim or standard of care in patients with immune thrombocytopenia.

@article{Kuter2010RomiplostimOS,
  title={Romiplostim or standard of care in patients with immune thrombocytopenia.},
  author={D. J. Kuter and M. Rummel and R. Boccia and B. Macik and I. Pabinger and D. Selleslag and F. Rodeghiero and B. Chong and Xuena Wang and D. Berger},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 20},
  pages={
          1889-99
        }
}
  • D. J. Kuter, M. Rummel, +7 authors D. Berger
  • Published 2010
  • Medicine
  • The New England journal of medicine
  • BACKGROUND Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients with immune thrombocytopenia, with few adverse effects. METHODS In this open-label, 52-week study, we randomly assigned 234 adult patients with immune thrombocytopenia, who had not undergone splenectomy, to receive the standard of care (77 patients) or weekly subcutaneous injections of romiplostim (157 patients). Primary end points were incidences of treatment failure and splenectomy. Secondary end points… CONTINUE READING
    309 Citations

    Paper Mentions

    Interventional Clinical Trial
    Chemotherapy used in the treatment of primitive tumors of the central nervous system has a particularly important platelet toxicity compared to chemotherapy used for treatment of other… Expand
    ConditionsGlioblastoma, Thrombocytopenia
    InterventionDrug
    Use of Romiplostim for Primary Immune Thrombocytopenia in Children
    • 21
    Romiplostim: a review of its use in immune thrombocytopenia.
    • 12
    • Highly Influenced
    Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
    • 173
    Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care
    • 18
    • Highly Influenced
    Health‐related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care
    • 53

    References

    SHOWING 1-10 OF 28 REFERENCES
    Treatment options for chronic idiopathic (immune) thrombocytopenic purpura.
    • 21